Group 1 - The core point of the article is that Basestone Pharmaceuticals' drug, Pujihua (Pralsetinib), has been included in the latest National Medical Insurance Drug List in China, effective from January 1, 2026 [1] - Pujihua is an oral targeted therapy approved for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for certain thyroid cancer patients [1] - The drug has already been approved in Hong Kong and Taiwan for similar indications, demonstrating its regional market presence [1] Group 2 - The FDA has approved Pujihua under the brand name GAVRETO for specific indications related to metastatic RET fusion-positive NSCLC and thyroid cancer in adults and children aged 12 and above [2] - Pujihua was developed by Blueprint Medicines, which was acquired by Sanofi in July 2025, while Basestone Pharmaceuticals holds exclusive rights for its development and commercialization in Greater China [2] - In November 2023, Basestone Pharmaceuticals granted exclusive commercialization rights for Pujihua in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [2]
基石药业-B：普吉华 (普拉替尼胶囊)获纳入2025年国家医保目录